Carmen Gonzalez

Carmen Gonzalez

Auto-generated profile, based on publicly available information

Carmen Gonzalez

Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2026 in Blood
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
DZDavid Zihala
David Zihala
AZAintzane Zabaleta
Aintzane Zabaleta
IKIoannis Kostopoulos
Ioannis Kostopoulos
Ondrej SoucekOndrej Soucek
Ondrej Soucek
RHRoman Hajek
Roman Hajek
Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti–B-cell maturation antigen (BCMA) and anti–G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P< .001), and normal PCs, from 0.17% to <0.0002% (P< .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.

7 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HKHana Komic
Hana Komic
TSTessa Schmachtel
Tessa Schmachtel
CSCatia Simoes
Catia Simoes
MKMarius Külp
Marius Külp
WYWeijia Yu
Weijia Yu
MRMichael A Rieger
Michael A Rieger
Uncovering early gene network changes of human hematopoietic stem cells (HSCs) leading to differentiation induction is of utmost importance for therapeutic manipulation. We employed single cell proteo-transcriptomic sequencing to FACS-enriched bone marrow hematopoietic stem and progenitor cells (HSPCs) from 15 healthy donors. Pseudotime analysis reveals four major differentiation trajectories, which remain consistent upon aging, with an early branching point into megakaryocyte-erythroid progenitors. However, young donors suggest a more productive differentiation from HSPCs to committed progenitors of all lineages. tradeSeq analysis depicts continuous changes in gene expression of HSPC-related genes (DLK1, ADGRG6), and provides a roadmap of gene expression at the earliest branching points. We identify CD273/PD-L2 to be highly expressed in a subfraction of immature multipotent HSPCs with enhanced quiescence. Functional experiments confirm the immune-modulatory function of CD273/PD-L2 on HSPCs in regulating T-cell activation and cytokine release. Here, we present a molecular map of early HSPC differentiation across human life.

21 August 2025 in Blood
Verified
Journal Article
Closed access
MLMarta Lasa
Marta Lasa
CGCarmen Gonzalez
Carmen Gonzalez
LNLaura Notarfranchi
Laura Notarfranchi
AZAnastasiia Zherniakova
Anastasiia Zherniakova
DADiego Alignani
Diego Alignani
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward more frequent readouts of tumor kinetics while preserving quality of life. We present BloodFlow, a new method combining immunomagnetic enrichment of CD138+ circulating plasma cells in peripheral blood (PB) with next-generation flow (NGF), for the detection of PRD below the 2 × 10–6 NGF threshold. BloodFlow detected PRD in 55 of 644 PB samples (8.5%) from 295 patients. Of note, 52.7% PB samples were positive using BloodFlow and negative by NGF. The lowest PRD detected by BloodFlow was 6 × 10–8. Using bone marrow measurable residual disease (MRD) status as the reference, BloodFlow showed positive and negative predictive values of 95.1% and 76.6%, respectively. Detectable PRD during maintenance or observation predicted dismal PFS and overall survival (2-year rates of 0% and 62%, respectively). BloodFlow surpassed NGF in PB and retained independent prognostic value for PFS in multivariate analysis, including transplant eligibility, the revised International Staging System, complete remission, and MRD status. BloodFlow is the first flow cytometry method that detects tumor cells below the 10–6 threshold, enabling improved minimally invasive monitoring of patients with MM.

10 January 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MLMarta Lasa
Marta Lasa
LNLaura Notarfranchi
Laura Notarfranchi
CACristina Agullo
Cristina Agullo
CGCarmen Gonzalez
Carmen Gonzalez
SCSergio Castro
Sergio Castro
PGPETHEMA/GEM Cooperative Group
PETHEMA/GEM Cooperative Group
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In multiple myeloma (MM), measurable residual disease (MRD) is assessed in bone marrow (BM). However, less invasive evaluation of peripheral residual disease (PRD) in blood could be advantageous and less cumbersome. We investigated the prognostic value of PRD monitoring after 24 cycles of maintenance in 138 transplant-eligible patients with MM enrolled in the GEM2012MENOS65/GEM2014MAIN clinical trials. PRD was assessed using next-generation flow (NGF) and mass spectrometry (MS). Positive PRD by NGF in 16/138 (11.5%) patients was associated with a 13-fold increased risk of progression and/or death; median progression-free survival (PFS) and overall survival (OS) were 2.5 and 47 months, respectively. Considering patients' MRD status in BM as the reference, PRD detection using NGF showed positive and negative predictive values of 100% and 73%, respectively. Presence of PRD helped identifying patients at risk of imminent progression among those with positive MRD in BM. Patients with undetectable PRD according to both NGF and MS showed 2-year PFS and OS rates of 97% and 100%, respectively. In multivariate analyses including the Revised International Staging System and the complete remission status, only MRD in BM and PRD by NGF showed independent prognostic value for PFS. This study supports the use of less invasive PRD monitoring during maintenance or observation in transplant-eligible patients with MM.

18 June 2026 in HemaSphere
Verified
Journal Article
Open access
NBNatalia Buenache
Natalia Buenache
MLMarta Lasa
Marta Lasa
AAAndrés Arroyo
Andrés Arroyo
CGCarmen González
Carmen González
LHLarissa Haertle
Larissa Haertle
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Measurable residual disease assessment in bone marrow (BM‐MRD) is a crucial prognostic factor in multiple myeloma (MM), but its clinical use has some caveats, such as invasiveness, poor spatial representativity, and serial sampling. Novel minimally invasive approaches for monitoring peripheral residual disease (PRD) could facilitate its clinical use. We aimed to investigate a sensitive method for detecting PRD in patients with MM. This study included 84 patients enrolled in PETHEMA/GEM clinical trials, and a total of 292 longitudinal samples were analyzed. BM‐MRD in these patients was assessed using EuroFlow‐based next‐generation flow cytometry (NGF) and PRD was simultaneously examined in cell‐free DNA (cfDNA) using AltumTrackSeq®, a highly sensitive next‐generation sequencing (NGS) method based on patient‐specific multiplexed amplicon mini‐panels that target somatic mutations identified at diagnosis. Our findings revealed that automated isolation methods enabled standardization and yielded cfDNA levels comparable to manual protocols. A high median cfDNA concentration of 393.2 ng was obtained, with a range from 17.3 to 6300 ng. Furthermore, we demonstrated that compared with traditional BM‐MRD by NGF, our ctDNA‐NGS approach showed a higher positive predictive value (PPV, 88.9% vs. 34.5%) and specificity (Sp, 98.4% vs. 70.3%) for predicting relapse during the follow‐up period. Detectable ctDNA was associated with a high risk of progression and/or death (HR, 11.5; 95% CI, 2.66–49.4), and this was confirmed in the multivariate analysis. In conclusion, this assay offers a method for detecting imminent relapse risk in the peripheral blood of MM patients.

5 November 2026 in Blood
Verified
Journal Article
Closed access
CGCarmen Gonzalez
Carmen Gonzalez
CGCamila Guerrero
Camila Guerrero
MLMarta Larrayoz
Marta Larrayoz
AZAintzane Zabaleta
Aintzane Zabaleta
JZJunfei Zhao
Junfei Zhao
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
The clinical significance of 1 or 2 measurable residual disease (MRD) assessments is established in multiple myeloma (MM). However, how to stratify patients according to ≥3 MRD assessments remains unknown. The traits of MRD resistance and whether treatment of persistent MRD vs relapse could improve outcomes remains unknown. MRD dynamics were computed using next-generation flow cytometry and CONNECTOR in 539 patients with newly diagnosed MM with ≥3 assessments in the GEM2012MENOS65/GEM2014MAIN and GEM2017FIT trials. Molecular and immune profiling were performed in matched diagnostic and MRD samples. The survival impact of treating persistent MRD vs relapse was investigated with anti–B-cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T cells in MIcγ1hCRBN mice. Computed MRD dynamics based on 3610 MRD assessments identified 5 subgroups with different survival. Patients with late-sustained MRD response had excellent outcomes, similar to those with early sustained MRD response. Patients with volatile results and those with primarily and resurgent MRD resistance had dismal survival. MRD dynamics outperformed transplant eligibility and the Revised International Staging System. These results were validated in 249 patients with MM treated in routine practice. Multiomics characterization of MRD dynamics in patients and mouse models of MRD resistance revealed genomic evolution, transcriptional adaptation, and a proinflammatory tumor-immune microenvironment. Increasing clonality and exhaustion of endogenous T cells throughout disease progression urged investigating whether MRD interception with anti-BCMA CAR T cells could improve outcomes. Infusion at MRD resistance prolonged mouse survival compared with identical treatment at relapse. In summary, MRD dynamics is the strongest predictor of progression and may help tailoring treatment to prevent additional tumor and immune alterations before relapse.